Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sulforaphane,Alpha-Cyclodextrin

            Therapeutic Area: Infections and Infectious Diseases Product Name: SFX-01

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: University of Dundee

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2021

            Details:

            A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azithromycin,Lopinavir,Ritonavir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality (19% azithromycin vs. 19% usual care) There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Colchicine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 27, 2020

            Details:

            Randomised Evaluation of COVid-19 Therapy (RECOVERY) trial will investigate colchicine, a commonly used anti-inflammatory treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AB201

            Therapeutic Area: Infections and Infectious Diseases Product Name: rNAPc2

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            AB201 is the only novel compound being developed for COVID Associated Coagulopathy. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 18, 2020

            Details:

            Results were published in the Lancet. The paper reported data on 560 people enrolled in the phase 2 portion of the phase 2/3 clinical trial of the ChAdOx1 nCoV-19 vaccine AstraZeneca is developing with the University of Oxford.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VIR-7831

            Therapeutic Area: Infections and Infectious Diseases Product Name: GSK4182136

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vir Biotechnology

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable